Description:

Size: 100ul

Catalog no.: bs-15455R-A555

Price: 380 EUR

Product details

Modification Site

None

Crossreactivity

Virus

Target Antigen

HBcAg

Tested applications

IF(IHC-P)

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Concentration

1ug per 1ul

Excitation emission

553nm/568nm

Conjugated with

ALEXA FLUOR® 555

Cross-reactive species details

Hepatitis B Virus

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR 555

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-HBcAg PAb ALEXA FLUOR 555

Specificity

This is a highly specific antibody against HBcAg.

Long name

HBcAg Polyclonal Antibody, ALEXA FLUOR 555 Conjugated

Source

KLH conjugated synthetic peptide derived from Hepatitis B Virus Core Antigen

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Synonyms

C; Capsid protein; Core and e antigen; Core antigen; Core antigen; Core protein; HBc; HBcAg; HBVgp4; Hepatitis B Virus core antigen; p21.5; precore/core protein; CAPSD_HBVA3.

Properties

For facs or microscopy Alexa 1 conjugate.Very high photo stable ALEXA conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.